LSE - Delayed Quote GBp

Oxford Biomedica plc (OXB.L)

333.50
-4.00
(-1.19%)
At close: 4:35:12 PM GMT+1
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
128,797
128,797
89,539
139,989
142,797
Cost of Revenue
75,776
75,776
49,812
70,808
60,157
Gross Profit
53,021
53,021
39,727
69,181
82,640
Operating Expense
96,523
96,523
127,836
120,739
61,707
Operating Income
-43,502
-43,502
-88,109
-51,558
20,933
Net Non Operating Interest Income Expense
-7,269
-7,269
-6,289
-7,781
-888
Pretax Income
-47,265
-47,265
-188,527
-45,976
19,880
Tax Provision
1,344
1,344
-4,365
-817
869
Net Income Common Stockholders
-43,190
-43,190
-157,490
-39,157
19,011
Diluted NI Available to Com Stockholders
-43,190
-43,190
-157,490
-39,157
19,011
Basic EPS
-0.42
--
-1.63
-0.41
0.23
Diluted EPS
-0.42
--
-1.63
-0.41
0.22
Basic Average Shares
103,458.25
--
96,555.35
94,829.89
83,484.17
Diluted Average Shares
103,458.25
--
96,555.35
94,829.89
85,618.67
Total Operating Income as Reported
-39,375
-39,375
-184,174
-30,220
20,768
Rent Expense Supplemental
471
471
249
231
236
Total Expenses
172,299
172,299
177,648
191,547
121,864
Net Income from Continuing & Discontinued Operation
-43,190
-43,190
-157,490
-39,157
19,011
Normalized Income
-46,150
-46,150
-61,499.17
-60,115.82
19,168.79
Interest Income
3,236
3,236
4,910
973
0
Interest Expense
10,505
10,505
11,199
8,754
888
Net Interest Income
-7,269
-7,269
-6,289
-7,781
-888
EBIT
-36,760
-36,760
-177,328
-37,222
20,768
EBITDA
-14,333
-14,333
-148,618
-10,863
33,224
Reconciled Cost of Revenue
75,776
75,776
49,812
70,808
60,157
Reconciled Depreciation
22,427
22,427
28,710
26,359
12,456
Net Income from Continuing Operation Net Minority Interest
-43,190
-43,190
-157,490
-39,157
19,011
Total Unusual Items Excluding Goodwill
1,652
1,652
-98,266
21,338
-165
Total Unusual Items
-69
-69
-98,266
21,338
-165
Normalized EBITDA
-14,264
-14,264
-50,352
-32,201
33,389
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
413
413
-2,275.17
379.18
-7.21
12/31/2021 - 12/13/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SCLP.L Scancell Holdings plc
10.50
0.00%
 
FAB.L Fusion Antibodies plc
6.45
-3.01%
 
ONT.L Oxford Nanopore Technologies plc
123.90
+0.24%
 
VAL.L ValiRx plc
0.4500
0.00%
 
BVXP.L Bioventix PLC
2,800.00
0.00%
 
AVCT.L Avacta Group Plc
36.50
+10.61%
 
0775.HK CKLIFE SCIENCES
0.910
0.00%
 
HVO.L hVIVO plc
11.88
+5.56%
 
GMAB Genmab A/S
22.84
+2.65%
 
IPSC Century Therapeutics, Inc.
0.6348
+1.28%